Mode
Text Size
Log in / Sign up

Salvage radiotherapy for limited metastatic relapse in small cell lung cancer after durvalumabTwo patients with limited-stage small cell lung cancer had durable disease control after salvage radiotherapy and immunotherapy

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Consider salvage radiotherapy as a feasible option for limited metastatic relapse in select small cell lung cancer patients post-immunotherapy, based on limited case evidence.

This hypothesis-generating case report describes two patients with limited-stage small cell lung cancer who developed limited metastatic relapse after concurrent chemoradiotherapy and durvalumab consolidation. The intervention was salvage radiotherapy, including adrenal hypofractionated radiotherapy (54 Gy in 15 fractions to GTV and 45 Gy in 15 fractions to PTV) and whole-brain radiotherapy with simultaneous integrated boost (40 Gy in 10 fractions to metastatic foci and 30 Gy in 10 fractions to the whole brain).

The main result was durable disease control in both patients over a follow-up exceeding four years. No specific effect size, p-value, or confidence interval was reported. Safety and tolerability data were not reported.

Key limitations include the evidence in SCLC being limited and optimal salvage strategies after immunotherapy remaining unclear. The practice relevance suggests that curative-intent local radiotherapy may be feasible and warrants prospective evaluation in carefully selected patients. This is hypothesis-generating clinical observations with limited evidence.

This study examines a very small group of patients with a specific type of lung cancer. The participants were two individuals diagnosed with limited-stage small cell lung cancer who experienced a limited metastatic relapse after completing their initial chemotherapy, radiation, and durvalumab consolidation. Following this relapse, the medical team administered salvage radiotherapy to specific areas, including the adrenal glands and brain lesions, while continuing immunotherapy.

The main finding was that both patients achieved durable disease control. They remained stable for a period exceeding four years after receiving this combination of treatments. No adverse events or serious safety concerns were reported for these two patients during the follow-up period. The study notes that the optimal strategies for treating recurrence after immunotherapy remain unclear.

Readers should understand that this evidence is limited because it is based on only two cases. While the results suggest that curative-intent local radiotherapy may be feasible for carefully selected patients, this finding warrants prospective evaluation in larger studies. This report should not be taken as proof that this treatment will work for all patients with similar conditions.

What this means for you:
Two patients had durable control after salvage radiotherapy, but evidence is limited and needs larger studies.

Study Details

Study typeCohort
EvidenceLevel 3
PublishedApr 2026
View Original Abstract ↓
The ADRIATIC trial demonstrated that consolidation durvalumab after concurrent chemoradiotherapy (cCRT) improves progression-free survival (PFS) and overall survival (OS) in limited-stage small cell lung cancer (LS-SCLC), establishing a new standard of care. However, a proportion of patients still develop distant relapse, and optimal salvage strategies after immunotherapy remain unclear. While metastasis-directed radiotherapy, including stereotactic radiotherapy and hypofractionated radiotherapy, has shown benefit in selected oligometastatic non–small cell lung cancer (NSCLC), evidence in SCLC is limited. Here, we describe two LS-SCLC patients who developed limited metastatic relapse after cCRT followed by durvalumab consolidation: one with a solitary adrenal metastasis and the other with two brain metastases. Both patients received salvage radiotherapy (adrenal hypofractionated radiotherapy: 54 Gy in 15 fractions to GTV and 45 Gy in 15 fractions to PTV; brain lesions treated with whole-brain radiotherapy with simultaneous integrated boost [WBRT-SIB]: 40 Gy in 10 fractions to metastatic foci and 30 Gy in 10 fractions to the whole brain). Both patients experienced durable disease control exceeding four years without additional systemic therapy during follow-up. These two cases provide hypothesis-generating clinical observations suggesting that, in carefully selected LS-SCLC patients with limited metastatic relapse, curative-intent local radiotherapy may be feasible and warrants prospective evaluation.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.